| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/27/2006 | WO2006077419A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | WO2006077416A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | WO2006077414A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | WO2006077407A2 Modulators of itch ubiquitinase activity |
| 07/27/2006 | WO2006077168A1 Pyrazolopyridines, their preparation and their medical use |
| 07/27/2006 | WO2006077166A1 Use of gallium (iii) complexes for treating tumours of the urothelial tract |
| 07/27/2006 | WO2006076863A1 The synergistically pharmaceutical composition for inhibiting tumor |
| 07/27/2006 | WO2006076854A1 Combination medication for malignant tumors and application |
| 07/27/2006 | WO2006061712A3 Use of mek inhibitors in treating abnormal cell growth |
| 07/27/2006 | WO2006054143A8 Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine |
| 07/27/2006 | WO2006050246A3 Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles, their manufacturing and their use for diagnostics and therapy |
| 07/27/2006 | WO2006036981A3 Small molecule modulators of cytokine activity |
| 07/27/2006 | WO2006029275A3 Methods of using death receptor ligands and cd20 antibodies |
| 07/27/2006 | WO2006013203A3 Prodrugs activated by rna-dependent dna-polymerases |
| 07/27/2006 | WO2006001967A3 Migrastatin analogs in the treatment of cancer |
| 07/27/2006 | WO2005114206A3 Diagnostics and therapeutics for diseases associated with serotonin 5-ht5a receptor (5ht5a) |
| 07/27/2006 | WO2005111078A3 Anti-cea scfv-beta-lactamase contructs (cab molecules) in adept |
| 07/27/2006 | WO2005075454A3 SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE |
| 07/27/2006 | US20060168667 Minibrain homologous proteins involved in the regulation of energy homeostasis |
| 07/27/2006 | US20060167261 e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty |
| 07/27/2006 | US20060167223 Novel ampiphilic fluorocarbon molecular vectors for biomedical and medical use |
| 07/27/2006 | US20060167086 Medicinal composition |
| 07/27/2006 | US20060167083 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 07/27/2006 | US20060167080 Use in inhibiting PI-3-kinase activity in mammals; cancer; Acetic acid 4-diallylaminomethylene-6-hydroxy-1- alpha -methoxymeth-yl-10 beta ,13 beta -dimethyl-3,7,17-trioxo-1,3,4,7,10,11 beta , 12,13,14 alpha ,15,16,17-dodecahydro-2-oxa-cyclopenta[ alpha ]phenanthren-11-yl ester |
| 07/27/2006 | US20060167067 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent |
| 07/27/2006 | US20060167065 Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| 07/27/2006 | US20060167049 Terphenly derivatives, preparation thereof, compositions containing same |
| 07/27/2006 | US20060167043 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 07/27/2006 | US20060167037 Combinational radiotherapy and chemotherapy compositions and methods |
| 07/27/2006 | US20060167036 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor |
| 07/27/2006 | US20060167033 viral infections; lung tumor and gastric cancer; 7-2-(2-aminophenyldithio)phenyliminomethylcamptothecin |
| 07/27/2006 | US20060167027 Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 07/27/2006 | US20060167024 Cancer combination therapy comprising azd2171 and zd1839 |
| 07/27/2006 | US20060167015 Inhibitors of tyrosine kinases |
| 07/27/2006 | US20060167011 Inhibitors of phosphorylation of platelet derived growth factor receptor |
| 07/27/2006 | US20060167007 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
| 07/27/2006 | US20060167003 Probucol derivatives |
| 07/27/2006 | US20060166990 Novel aminobenzophenone compounds |
| 07/27/2006 | US20060166988 Novel compounds |
| 07/27/2006 | US20060166978 Inhibitors of IkB kinase (I Kappa B Kinase); 1-acetyl-7-bromo- beta -carboline; antiinflammatory and anticarcinogenic agent; asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, infections, and cardiac infarct |
| 07/27/2006 | US20060166976 Compositions and methods for treating or preventing convulsions or seizures |
| 07/27/2006 | US20060166970 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation |
| 07/27/2006 | US20060166952 Cardenolide glycosides, which have a cytotoxic activity, cancer |
| 07/27/2006 | US20060166940 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases |
| 07/27/2006 | US20060166934 Composition comprising phytosphingosine derivatives for apoptosis induction |
| 07/27/2006 | US20060166927 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 07/27/2006 | US20060166925 Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
| 07/27/2006 | US20060166907 Composition for the treatment of nasopharyngeal carcinoma and method of use thereof |
| 07/27/2006 | US20060166892 Treatment of cell proliferative disorders with chlorotoxin |
| 07/27/2006 | US20060166870 Treatment of glioblastoma with thymosin-alpha 1 |
| 07/27/2006 | US20060166868 Vegf peptides and their use |
| 07/27/2006 | US20060166863 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 07/27/2006 | US20060166862 Comprising a transcobalamin (TC) binding carrier and a therapeutic and/or diagnostic agent linked directly or through linker to the TC binding carrier; highly and efficiently absorbed |
| 07/27/2006 | US20060166255 Methods of using 48149, a human Aminopeptidase family member |
| 07/27/2006 | US20060166213 Novel compositions and methods in cancer |
| 07/27/2006 | US20060166194 Diagnosis and treatment of cancer |
| 07/27/2006 | US20060165825 Pharmaceutical compositions |
| 07/27/2006 | US20060165821 Composition comprising scutellaria baicalensis and their uses thereof |
| 07/27/2006 | US20060165816 Herbal compositions useful as chemopreventive and therapeutic agents |
| 07/27/2006 | US20060165771 Compositions for delivery of drug combinations |
| 07/27/2006 | US20060165744 Combination liposomal formulations |
| 07/27/2006 | US20060165727 Vaccine; inducing an immune response; infectious diseases, which can be caused by more than one strain, clade, variant, subtype or serotype of infectious disease causing microorganism; reliable vaccination against all Dengue virus serotypes |
| 07/27/2006 | US20060165726 Remedies with the use of hollow protein nanoparticles presenting growth factor or the like |
| 07/27/2006 | US20060165724 Method of producing infectious reovirus |
| 07/27/2006 | US20060165709 stimulate T cytotoxic lymphocytes in a mammal |
| 07/27/2006 | US20060165708 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| 07/27/2006 | US20060165701 Agents for the diagnosis and treatment of tumors that expose alerted proteins on the cell surface |
| 07/27/2006 | US20060165699 Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role |
| 07/27/2006 | US20060165695 Antibody against human insulin-like growth factor |
| 07/27/2006 | US20060165693 treating a patient having cancer |
| 07/27/2006 | US20060165692 Humanized anti-CD3 specific antibodies |
| 07/27/2006 | US20060165691 Humanized anti-CD3 specific antibodies |
| 07/27/2006 | US20060165678 Measuring changes in level of antigen recognizable by a monoclonal antibody or antigen binding fragment; monoclonal antibody is produced by hybridoma cell line; decreased level indicates a reduced tumor; diagnosis, cell purification |
| 07/27/2006 | US20060165656 Medicinal preparation having chemotherapeutic encapsulated therein |
| 07/27/2006 | US20060165652 Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| 07/27/2006 | US20060165600 Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same |
| 07/27/2006 | DE112004001563T5 Säure-haltige Oxaliplatin-Formulierungen Acid-containing oxaliplatin formulations |
| 07/27/2006 | DE102005002500A1 Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen Tetrahydrofuran derivatives as inhibitors of matrix metalloproteinases |
| 07/27/2006 | CA2619153A1 Regulation of protein synthesis by inhibition of eif4e-eif4g interaction |
| 07/27/2006 | CA2598607A1 Methods and compositions for cell-cycle regulation |
| 07/27/2006 | CA2595461A1 Method for producing albumin conjugates containing gyrase inhibitors |
| 07/27/2006 | CA2595127A1 Mitotic kinesin inhibitors |
| 07/27/2006 | CA2595063A1 Emulsified composition for dilution and cancer vaccine composition |
| 07/27/2006 | CA2594482A1 Antitumor agent |
| 07/27/2006 | CA2594477A1 Pharmaceutical compounds |
| 07/27/2006 | CA2594474A1 Pharmaceutical compounds |
| 07/27/2006 | CA2593656A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | CA2593560A1 4- (2, 6-dichlorobenzoylamino) -lh-pyrazole-3 -carboxylic acid piperidin- 4 -ylamid acid addition salts as kinase inhibitors |
| 07/27/2006 | CA2593475A1 Combinations of pyrazole kinase inhibitors and further antitumor agents |
| 07/27/2006 | CA2593468A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | CA2593465A1 Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
| 07/27/2006 | CA2592172A1 Modulators of itch ubiquitinase activity |
| 07/27/2006 | CA2575547A1 Substituted quinobenzoxazine analogs and methods of using thereof |
| 07/27/2006 | CA2563823A1 Beta-peptides |
| 07/27/2006 | CA2562685A1 Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
| 07/26/2006 | EP1683811A2 Compositions and methods for the treatment of tumors |
| 07/26/2006 | EP1683807A1 Combination products for use in antitumoral treatment, comprising an antibody capable of inhibiting the activity of CSF-1 |
| 07/26/2006 | EP1683803A1 Water soluble prodrugs of hindered alcohols or phenols |
| 07/26/2006 | EP1683796A1 Pyrazolopyridines, their preparation and their medical use |
| 07/26/2006 | EP1683523A1 2-Phenylquinoxalines as inhibitors for MPP1 |